APR 26, 2018
Episurf Medical (NASDAQ: EPIS B) today announces that the company has entered into a distribution agreement in Hong Kong with Pacific Medical Systems. This is a first step in the company’s strategy of opening new markets in Asia. Pål Ryfors, CEO Episurf Medical, says that “we have received very encouraging feedback from leading surgeons in Hong Kong, confirming that Episealer® will help them to treat patients in the so-called treatment gap. We are happy to have appointed Pacific Medical Systems as our distributor, and Hong Kong will, as our first market in Asia where our technology is ready to be marketed, also be an important reference during our further expansion in the region.”
The company also communicates that it has established a subsidiary in the US, Episurf Medical Inc. This subsidiary is established for the purpose of conducting clinical studies for regulatory purposes in the US, as previously communicated.
For more information, please contact:
Pål Ryfors, CEO, Episurf Medical
Tel:+46 (0) 709 62 36 69
About Episurf Medical
Episurf Medical is endeavoring to bring people with painful joint injuries a more active, healthier life through the availability of minimally invasive and personalized treatment alternatives. Episurf Medical’s Episealer® personalized implants and Epiguide® surgical drill guides are developed for treating localized cartilage injury in joints. Episurf Medical’s μiFidelity® system enables implants to be cost-efficiently tailored to each individual’s unique injury for the optimal fit and minimal intervention. Episurf Medical’s head office is in Stockholm, Sweden. Its share (EPIS B) is listed on Nasdaq Stockholm. For more information, go to the company’s website: www.episurf.com.